Phaxiam Therapeutics Aktie
Personal
| 2010 | 2011 | 2012 | 2013 | 2014 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 39 | 36 | 44 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2010 | 2011 | 2012 | 2013 | 2014 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 5 | 4 | 9 | 17 | 40 |
| Summe Anlagevermögen | 1 | 1 | 1 | 1 | 1 |
| Summe Aktiva | 7 | 5 | 10 | 18 | 41 |
Bilanz (in Mio. EUR) - Passiva
| 2010 | 2011 | 2012 | 2013 | 2014 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 3 | 7 | 14 | 4 | 5 |
| Summe Eigenkapital | 4 | -2 | -4 | 14 | 36 |
| Summe Passiva | 7 | 5 | 10 | 18 | 41 |
Adresse
| 60, avenue Rockefeller, 69008 Lyon | |
| Telefon | +33 (4) 78-74-44-38 |
| Internet | http://www.phaxiam.com |
Management
|
Anne-Cécile Fumey
Director-Human Resources |
|
Cindy Fevre
Chief Scientific Officer |
|
Céline Breda
Chief Technical Officer |
|
Didier Hoch
Chairman |
|
Eric Jean Marie Leire
Independent Director |
|
Eric Soyer
Deputy CEO, Chief Financial & Operating Officer |
|
Frédérique Vieville
Chief Regulatory Officer |
|
Gil Beyen
Vice Chairman |
|
Hilde Windels
Independent Director |
|
Jérôme Bailly
Chief Quality Officer & Deputy CEO |
|
Karine Charton
Chief Business Officer |
|
Leila Nicolas
Director |
|
Martine Ortin George
Independent Director |
|
Pascal Birman
Chief Medical Officer |
|
Philippe Archinard
Independent Director |
|
Robert Sebbag
Independent Director |
|
Thibaut du Fayet
Chief Executive Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.